Article info

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

Authors

  1. Correspondence to Dr Ulf Lindström, Department of Rheumatology and Inflammation Research, University of Gothenburg Sahlgrenska Academy, 405 30 Gothenburg, Sweden; ulf.lindstrom{at}gu.se
View Full Text

Citation

Lindström U, Bengtsson K, Olofsson T, et al
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

Publication history

  • Received March 23, 2021
  • Accepted June 5, 2021
  • First published June 15, 2021.
Online issue publication 
October 12, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.